FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912973389> ?p ?o ?g. }

• W2912973389 endingPage "2302" @default.
• W2912973389 startingPage "2292" @default.
• W2912973389 abstract "Vildagliptin (VIL) and saxagliptin (SAX) are two covalent drugs for the treatment of type 2 diabetes mellitus. The principal pharmacological effects of VIL and SAX are known to arise from their biochemical reactions at the active site of dipeptidyl peptidase-4 (DPP-4), a serine protease that rapidly inactivates incretin hormones in plasma. However, the details of the catalytic mechanisms and the origin of the different pharmacokinetics behavior for the two scaffold-similar drugs are less clear. By employing quantum mechanical/molecular mechanical molecular dynamics simulations in this work, it is illuminated that the catalytic process involves two major steps: reversible covalent bonding which covalently modifies the antidiabetic target DPP-4 and irreversible hydrolysis reaction which converts the drugs into inactive metabolites. The reaction free energy profiles indicate that VIL is dissociated from DPP-4 mainly through the hydrolysis pathway, while SAX overwhelmingly through the reverse process of covalent bonding. Therefore, the inhibition is pseudoirreversible for VIL, while reversible for SAX. Further comparative studies reveal that the 4,5-methylene substituent of pyrrolidine ring in SAX is responsible for the different dissociation kinetics features and its higher inhibitory activity compared to the VIL. All these findings are in agreement with the previously reported experimental results and guidable for further covalent drug design toward DPP-4." @default.
• W2912973389 created "2019-02-21" @default.
• W2912973389 creator A5000916538 @default.
• W2912973389 creator A5026810840 @default.
• W2912973389 creator A5053447705 @default.
• W2912973389 creator A5065291000 @default.
• W2912973389 date "2019-02-05" @default.
• W2912973389 modified "2023-10-15" @default.
• W2912973389 title "Covalent Inhibition Mechanism of Antidiabetic Drugs—Vildagliptin vs Saxagliptin" @default.
• W2912973389 cites W1700986470 @default.
• W2912973389 cites W1805640194 @default.
• W2912973389 cites W1940622563 @default.
• W2912973389 cites W1964758803 @default.
• W2912973389 cites W1976161355 @default.
• W2912973389 cites W1976499671 @default.
• W2912973389 cites W1977395659 @default.
• W2912973389 cites W1978700514 @default.
• W2912973389 cites W1993177346 @default.
• W2912973389 cites W1994474796 @default.
• W2912973389 cites W1995077775 @default.
• W2912973389 cites W2003043766 @default.
• W2912973389 cites W2004417740 @default.
• W2912973389 cites W2007279789 @default.
• W2912973389 cites W2010922747 @default.
• W2912973389 cites W2011778618 @default.
• W2912973389 cites W2012129602 @default.
• W2912973389 cites W2016408686 @default.
• W2912973389 cites W2019750828 @default.
• W2912973389 cites W2019857898 @default.
• W2912973389 cites W2024124160 @default.
• W2912973389 cites W2038417675 @default.
• W2912973389 cites W2046966843 @default.
• W2912973389 cites W2047730645 @default.
• W2912973389 cites W2047997492 @default.
• W2912973389 cites W2049883071 @default.
• W2912973389 cites W2054285456 @default.
• W2912973389 cites W2064410761 @default.
• W2912973389 cites W2069123478 @default.
• W2912973389 cites W2072129976 @default.
• W2912973389 cites W2081739151 @default.
• W2912973389 cites W2084986417 @default.
• W2912973389 cites W2091638124 @default.
• W2912973389 cites W2096971003 @default.
• W2912973389 cites W2098083442 @default.
• W2912973389 cites W2102634481 @default.
• W2912973389 cites W2106140689 @default.
• W2912973389 cites W2112154906 @default.
• W2912973389 cites W2117458899 @default.
• W2912973389 cites W2120901082 @default.
• W2912973389 cites W2122976061 @default.
• W2912973389 cites W2124195135 @default.
• W2912973389 cites W2128408225 @default.
• W2912973389 cites W2147993766 @default.
• W2912973389 cites W2150697053 @default.
• W2912973389 cites W2156034391 @default.
• W2912973389 cites W2159929445 @default.
• W2912973389 cites W2165765596 @default.
• W2912973389 cites W2207535250 @default.
• W2912973389 cites W2321646611 @default.
• W2912973389 cites W2334497435 @default.
• W2912973389 cites W2418561030 @default.
• W2912973389 cites W2475311184 @default.
• W2912973389 cites W248383993 @default.
• W2912973389 cites W2510874222 @default.
• W2912973389 cites W2516888180 @default.
• W2912973389 cites W2517550655 @default.
• W2912973389 cites W2622009965 @default.
• W2912973389 cites W2623565822 @default.
• W2912973389 cites W2744856371 @default.
• W2912973389 cites W2752520345 @default.
• W2912973389 cites W3126119092 @default.
• W2912973389 doi "https://doi.org/10.1021/acscatal.8b05051" @default.
• W2912973389 hasPublicationYear "2019" @default.
• W2912973389 type Work @default.
• W2912973389 sameAs 2912973389 @default.
• W2912973389 citedByCount "13" @default.
• W2912973389 countsByYear W29129733892019 @default.
• W2912973389 countsByYear W29129733892020 @default.
• W2912973389 countsByYear W29129733892021 @default.
• W2912973389 countsByYear W29129733892022 @default.
• W2912973389 countsByYear W29129733892023 @default.
• W2912973389 crossrefType "journal-article" @default.
• W2912973389 hasAuthorship W2912973389A5000916538 @default.
• W2912973389 hasAuthorship W2912973389A5026810840 @default.
• W2912973389 hasAuthorship W2912973389A5053447705 @default.
• W2912973389 hasAuthorship W2912973389A5065291000 @default.
• W2912973389 hasConcept C134018914 @default.
• W2912973389 hasConcept C161790260 @default.
• W2912973389 hasConcept C178790620 @default.
• W2912973389 hasConcept C180577832 @default.
• W2912973389 hasConcept C181199279 @default.
• W2912973389 hasConcept C185592680 @default.
• W2912973389 hasConcept C21951064 @default.
• W2912973389 hasConcept C2776453732 @default.
• W2912973389 hasConcept C2778689049 @default.
• W2912973389 hasConcept C2779284873 @default.
• W2912973389 hasConcept C2780282729 @default.
• W2912973389 hasConcept C2781469919 @default.

• next